Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 670,614 shares, a decline of 77.9% from the April 30th total of 3,038,967 shares. Based on an average trading volume of 2,410,748 shares, the days-to-cover ratio is presently 0.3 days. Currently, 6.4% of the shares of the company are short sold.

Institutional Investors Weigh In On Calidi Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CLDI. Geode Capital Management LLC increased its position in Calidi Biotherapeutics by 41.7% during the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares in the last quarter. Warberg Asset Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the third quarter valued at $28,000. Virtu Financial LLC acquired a new stake in shares of Calidi Biotherapeutics during the fourth quarter valued at $25,000. Finally, DRW Securities LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter worth about $173,000. 12.53% of the stock is currently owned by institutional investors and hedge funds.

Calidi Biotherapeutics Stock Performance

NYSEAMERICAN CLDI traded down $0.01 during trading hours on Friday, hitting $0.18. 1,264,992 shares of the stock were exchanged, compared to its average volume of 2,611,033. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.15. The company has a market cap of $3.55 million, a price-to-earnings ratio of -0.04 and a beta of 1.38. Calidi Biotherapeutics has a 12-month low of $0.16 and a 12-month high of $19.20. The stock has a 50-day moving average of $0.23 and a 200 day moving average of $0.78.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.